Conclusion
In summary, NLR can be an important biomarker for assessing the
prognosis of patients with advanced tumors, especially NLR<3 is
an independent risk factor for survival time of patients with treated
metastatic colorectal cancer who receive immune checkpoint inhibitors.
Its elevated level is usually associated with poorer prognosis, which
helps doctors to develop more effective treatment strategies.